Raise standards for preclinical cancer research
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index; 3 of the 9 sources its claims cite were checked for support.
Overview
CoChat Summary
TL;DR
This Nature Comment argues that many landmark preclinical oncology findings are not reproducible and calls for higher standards in methods, reporting, and incentives. It reports that Amgen confirmed only 6 of 53 landmark papers (11%) and cites Bayer’s finding that about 25% of published preclinical studies could be validated.
Key findings
- In Amgen’s ten-year retrospective analysis, scientific findings were confirmed in only 6 of 53 “landmark” preclinical cancer papers (11%); non-reproduced studies often lacked blinding, relied on single experiments such as one Western blot, or presented selected data.
- Bayer HealthCare reported that only about 25% of published preclinical studies could be validated to the point at which projects could continue; published cancer research represented 70% of the studies analysed in that report, with possible overlap with Amgen’s 53 papers.
- Citation data showed non-reproduced articles in journals with impact factor >20 had a mean of 248 citations (range 3–800) versus 231 (range 82–519) for reproduced articles; for impact factor 5–19, non-reproduced articles had a mean of 169 citations (range 6–1,909) versus 13 (range 3–24) for reproduced articles.
- The authors recommend reporting negative data, blinding preclinical experiments, validating reagents, repeating critical experiments, avoiding single cell lines or models, requiring patient-selection biomarkers, and changing academic incentives.
Methods
- This is a Nature Comment/perspective, not a primary experimental study; it synthesizes Amgen’s ten-year retrospective analysis of experiments performed prospectively and cites a Bayer HealthCare report.
- Amgen selected 53 “landmark” papers describing completely new approaches or alternative clinical uses, attempted confirmation, used additional models, contacted original authors, exchanged reagents, and repeated experiments under the authors’ direction, occasionally in the original investigator’s laboratory.
- The analysis reports counts of confirmed findings and citation metrics from Google Scholar, May 2011; the recommendations are proposed changes rather than tested interventions.
Limitations
- Stated: validation attempts may have failed because of technical differences or difficulties despite efforts to ensure otherwise; additional models were used; when findings could not be reproduced, authors were contacted and experiments were repeated under their direction.
- Stated: papers were deliberately selected as “landmark” and described something completely new, so some data might not hold up; Bayer’s analysed studies may overlap with Amgen’s 53 papers.
- Evident: as a Comment, the text provides no detailed systematic protocol, inclusion criteria, statistical methods, or full dataset; the citation analysis is descriptive and limited to two impact-factor strata.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 1 Not valid · 6 Not checked · 12 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Sadly, clinical trials in oncology have the highest failure rate compared with other therapeutic areas.”
What the sources say
- Partly supportedcites [1] Hutchinson, L. & Kirk, R. Nature Rev. Clin. Oncol. 8, 189–190 (2011). sourceExperimental — accuracy not yet measured
The opening passage of our copy (labelled Abstract; page unavailable) says cancer-drug attrition is much higher than in other therapeutic areas, citing 5% of anticancer agents versus 20% of cardiovascular agents reaching licensure. That comparison covers development from preclinical activity through phase III, not failure rates specifically among clinical trials; it also does not explicitly establish a highest-rate ranking. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although we in the cancer field hoped that this would lead to more effective drugs, historically, our ability to translate cancer research to clinical success has been remarkably low 1 .”
What the sources say
- Supportedcites [1] Hutchinson, L. & Kirk, R. Nature Rev. Clin. Oncol. 8, 189–190 (2011). source
The opening passage (labeled Abstract in our copy; no page given) reports that only 5% of agents with preclinical anticancer activity are licensed after demonstrating sufficient efficacy in phase III testing. It also says cancer drug attrition is much higher than in other therapeutic areas, supporting the claim of historically low translation to clinical success. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In studies for which findings could be reproduced, authors had paid close attention to controls, reagents, investigator bias and describing the complete data set.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For results that could not be reproduced, however, data were not routinely analysed by investigators blinded to the experimental versus control groups.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigators frequently presented the results of one experiment, such as a single Western-blot analysis.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
12 more claims
Create a free account to see all 22 claims and every source verdict.
- It may state two separate claims as one. 2
- Probably not a substantial claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there are other more common sources of unreliability in the literature (41)(42)(43)(44)”
From Misconduct accounts for the majority of retracted scientific publications (2012) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many established scientific results in the social (49, 50) and biomedical (51-53) sciences cannot readily be replicated.”
From Misinformation in and about science (2021) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A landmark study conducted by Glenn Begley and his team in 2012 concluded that most cancer research studies were not reproducible, by alarmingly reporting that 47 of 53 published findings could not be replicated [13].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cell biology, two industrial laboratories reported success replicating the original results of landmark findings in only 11% and 25% of the attempted cases ( 10, 11 ).”
From Estimating the reproducibility of psychological science (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Concerns about reproducibility are widespread across disciplines ( 921 ).”
From Estimating the reproducibility of psychological science (2015) · cites this paper as [10]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
Do Pressures to Publish Increase Scientists' Bias? An Empirical Support from US States Data
Fanelli, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010271 · Cited by 805
High drug attrition rates—where are we going wrong?
Hutchinson, L., & Kirk, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.34 · Cited by 517
Drug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135
Raising the bar for cancer therapy models
Francia, G., & Kerbel, R. S. (2010) · Nature Biotechnology · doi:10.1038/nbt0610-561 · Cited by 54
Cited by
Items 2,501–2,600 of 2,889
Judging Research in the Doors of Irreproducibility Crisis Era
Flores-Guerrero, J. L. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-6
Impact Factor /= Impact: Lessons Learned from Research Evaluation
Bertzbach, L. D. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-10
Research Quality and How to Find It?
Rojas, L. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-15
Johnson, M. E., Chen, A., Faeder, J. R., Henning, P., Moraru, I. I., Meier‐Schellersheim, M., Murphy, R. F., Prüstel, T., Theriot, J. A., & Uhrmacher, A. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.02.185595
“…resolved models Over the past decade, there has been a humbling realization that a large fraction of published results in experimental biology, including many that have led directly to significant efforts toward drug development, cannot be reproduced (Begley and Ellis, 2012; Prinz et al., 2011).”
BackgroundJudging Research: How Should Research and Researchers Be Evaluated and Rewarded?
Muhammed, F. K. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-16
Mathematics in Current Science and in Scientific Evaluation
Rivera, I. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-12
Gualtierotti, R. (2015) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-9
Tangible and Non-Tangible Rewards- a Balancing Act
Sivapragasam, M. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-4
Judging Research: Is There Even a Need of Evaluating the Research?
Chauhan, P. S. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-14
Judging and Rewarding Research and Researchers: Beyond Bibliometrics
Sharma, A. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-5
Scientific Metrics: How Useful Are They?
Ogashawara, I. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-3
Should the Quality of the Journal Determine the Quality of the Research?
Yüksek, A. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6-7
Science Publishing's Napster Moment and the Coming Youtubes of SciencePreprint
Nicholson, J., & Pepe, A. (2019) · doi:10.22541/au.155793027.77287322
Allometric Scaling of Dietary Bioactives in Metabolic Research: The Present and Future
Whelan, J. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160608-00295
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.003
Perdue, W. L., Reus, V. I., & Yeamans, R. (2020) · medRxiv · doi:10.1101/2020.10.25.20212282
Young, S. S., Cheng, K.-C., Chen, J., Chen, S., & Kindzierski, W. B. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2010.10922
RNAi Screens: Triumphs and Tribulations
Seyhan, A. A., & Carini, C. (2014) · doi:10.1201/b16749-6
Best Practices in Scientific ComputingPreprint
Sanchez, R., Griffin, B. A., & McCaffrey, D. F. (2021) · arXiv (Cornell University)
The metabolic determinants of the response to ketone bodies in SH-SY5Y neuroblastoma cells
Alherz, M. (2020) · Arrow@dit (Dublin Institute of Technology)
The Solution to Science's Replication CrisisPreprint
Knuteson, B. (2016) · RePEc: Research Papers in Economics · doi:10.48550/arxiv.1609.03223 · Cited by 1
Scientific Basis for Assessment of Electronic Nicotine Delivery Products
Hoeng, J., Boué, S., & Peitsch, M. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820490-0.00003-1
Transparency and replication in alcohol research
Drax, K., & Munafò, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816720-5.00005-0
Replicability and Reproducibility in Drug Discovery
Novick, S. J., & Könings, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00030-x
Problems with the discrete psychotherapy approach
Bowins, B. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85049-0.00028-3
hafez, D. E. (2021) · المجلة الدولية لعلوم المكتبات و المعلومات · doi:10.21608/ijlis.2021.157855
Rißmann, R., & Zuiker, R. G. J. A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14823
“or without controls, high risk of bias in (open-label) preclinical research or insufficient rigor of quality control of the data.(3,4) In addition, reporting standards for non-clinical research have been”
BackgroundEvidence provided by high-impact cell culture studies does not support authors’ claimsPreprint
Özkaya, A. B., & Geyik, C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.12.439525
“Many agree that we need strategies in place to improve the 246 standards for pre-clinical research [5,8].”
BackgroundInfluentialOn the Value of Biomedical Research and Medical Care
Catillon, M. (2020) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Nie, Z., & Nie, Y. (2021) · Preprints.org · doi:10.20944/preprints202104.0760.v1
Meta Research: Replication of Significant Results --- Modeling the Effects of p-HackingPreprint
Ulrich, R., & Miller, J. O. (2020) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/tu7zr · Cited by 1
Claims and statistical inference in animal physical cognition research.Preprint
Farrar, B. G., Altschul, D., Fischer, J., van der Mescht, J., Placì, S., Troisi, C. A., Vernouillet, A., Clayton, N. S., & Ostojić, L. (2020) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/x5ya3
A Language for Modeling and Optimizing Experimental Biological Protocols
Cardelli, L., Kwiatkowska, M., & Laurenti, L. (2021) · Computation · doi:10.3390/computation9100107 · Cited by 3
Schmitt, N. D. (2020) · Digital Repository Service (Northeastern University) · doi:10.17760/d20398259
Physics to the rescue?Preprint
Saltelli, A., Fiore, M. D., & Spanò, F. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2107.07239 · Cited by 1
“…pains (Ravetz 2016) could include: Methodological and epistemological, as in the crisis of reproducibility proper (Ioannidis 2005; Begley and Ellis 2012; Open Science Collaboration (OSC) 2015), and in the convulsions of statistics (Amrhein, Greenland, and McShane 2019; Gelman 2019; Mayo…”
BackgroundFAIR and bias-free network modules for mechanism-based disease redefinitions
Hassan, A. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210707ah
Fitt, B., Loy, G., Christopher, E., Brennan, P. M., & Poon, M. T. C. (2021) · medRxiv · doi:10.1101/2021.09.04.21263119
“However, issues with reporting bias, suboptimal reporting quality, varying reproducibility and preclinical model representation of disease impede the success in finding new therapies.(14) The availability of survival data in publicly available data from cancer genomics programmes presents an opportunity for researcher…”
BackgroundSmith, A. J. (2021) · Laboratory animal science and medicine · doi:10.1007/978-3-030-66147-2_11
Woutersen-Windhouwer, S., Méndez, E., Sondervan, J., & Oort, F. J. (2020) · European Research Libraries Cooperation
Paving the Road for Replications: Experimental Results from an Online Research Bibliography
Zimmermann, C., Reed, W. R., & Coupé, T. (2021) · doi:10.20955/wp.2021.013
Standard meta-analysis methods are not robustPreprint
Young, S. S., & Kindzierski, W. B. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2110.14511 · Cited by 1
“Begley and Ellis 2012 noted that 47 of 53 claims coming from experimental biology failed to replicate.”
BackgroundSmith, A. J., Lambert, P. C., & Rutherford, M. J. (2021) · Research Square · doi:10.21203/rs.3.rs-1170348/v1
A comprehensive analysis of code and data availability in biomedical researchPreprint
Deshpande, D., Sarkar, A. P., Guo, R., & Mangul, S. (2021) · doi:10.31219/osf.io/xjd8r
Questionable Research Practices and Determinants of Their FrequencyPreprint
Alsalti, T. (2021) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/uqz2e
Questionable Research Practices and Determinants of Their FrequencyPreprint
Alsalti, T. (2021) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/mjvwu
Subjectivity, Truth, and Theological Anthropology
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.009
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.001
Motulsky, H. (2019) · De Boeck Supérieur eBooks · doi:10.3917/dbu.motul.2019.01.0533
Cusimano, C. (2021) · doi:10.1002/9781119808268.refs
The Practices Shaping the Entrepreneurial Subject
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.006
Acquiring the Virtue of Truth-Speaking in Science
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.008
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.011
Teleology and the Craft of Science
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.005
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.004
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.010
Reshaping the Entrepreneurial Subject of Science
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.007
Wisneski, L., Gurfein, B., Barsotti, T., Chevalier, G., Mills, P. J., & Muehsam, D. J. (2017) · Routledge eBooks · doi:10.1201/9781315153889-9 · Cited by 1
Future of Regulatory Safety Assessments
Bode, G., & Starck-Lantova, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-56637-5_71-2
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.002
Weisberg, H. I. (2014) · Wiley eBooks · doi:10.1002/9781118839539.biblio
The Biochemistry of Hyaluronan in the Interstitial Space
(2016) · Protein science series · doi:10.1201/9781315374307-4
seqgra: principled selection of neural network architectures for genomics prediction tasks
Krismer, K., Hammelman, J., & Gifford, D. K. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac101
Chapter 1: Key Methodological Issues in Researching Gifted Education and Advanced AcademicsPreprint
McBee, M. T. (2022) · EdArXiv (OSF Preprints) · doi:10.35542/osf.io/mfdr2
Schneider, J. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/vc3zg
SPARKing Drug Development for Alzheimer’s Disease in Academia
Mochly‐Rosen, D., & Grimes, K. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.039
Replication crisisPreprint
Quang-Loc, N. (2022) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/4wd5x
INDUSTRY AND RESEARCH COLLABORATION A MODEL FOR INDIA
Goel, R. (2022) · Innovare Journal of Business Management · doi:10.22159/ijbm.2020.v8i1.44743
Rajčáni, J., Vargová, L., Adamkovic, M., et al. (2022) · doi:10.31234/osf.io/bkq7e
Cohort Studies, Meta-analyses, and Clinical Trials in Childhood Hypertension
Larkins, N., & Craig, J. C. (2022) · Springer eBooks · doi:10.1007/978-3-319-31420-4_54-2
An Appraisal of the Drug Discovery Process in Neuroscience
Nwokike, M. O., Ghasi, S. I., Ezenwaeze, M. N., Ogbonna, A. O., Ezinwa, A. C., & Ofor, C. C. (2022) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2022/v17i230195
de Winter, J., & Dodou, D. (2017) · SpringerBriefs in applied sciences and technology · doi:10.1007/978-3-319-56964-2_3
Buie, M. (2017) · Routledge eBooks · doi:10.1201/9781315276465-2
Statistical Use and Misuse in Scientific Publications
Hoffman, J. I. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817084-7.00002-4
(2013) · Nature Medicine · doi:10.1038/nm1113-1358
(2016) · CRC Press eBooks · doi:10.1201/9781315382579-25
NSF 19-609 Proposal: Evaluating Rigor and Transparency Culture Change InitiativesPreprint
Nosek, B. A., Errington, T. M., Mellor, D. T., Soderberg, C. K., Krall, T., Grasty, F. L., Brooks, R. E., Greene, A., Buck, S., Rosa, S. L., et al. (2020) · MetArXiv (OSF Preprints) · doi:10.31222/osf.io/ecgb5
Research Integrity: Perspectives from Korea and the United States
Lee, I. J., & KALICHMAN, M. W. (2015) · Springer eBooks · doi:10.1007/978-981-287-079-7_63-1
Transitioning Discoveries from Cancer Genomics Research Laboratories into Pathology Practice
Jamaspishvili, T., & Squire, J. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_13
(2013) · Elsevier eBooks · doi:10.1016/b978-0-12-404576-7.09978-0
Significance Testing in Natural and Biological Systems: A ReviewPreprint
Kak, S. C. (2021) · doi:10.36227/techrxiv.14599836
(2016) · Elsevier eBooks · doi:10.1016/b978-0-12-799962-3.00008-2
Proactively maintaining publication standards
(2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.05.016
Les pratiques de recherche ouvertes en psychologiePreprint
Lantian, A. (2020) · doi:10.31234/osf.io/tdy62
Balas, E. A. (2018) · Wiley eBooks · doi:10.1002/9781119225898.ch8
Williams, M., & Trist, D. G. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.11.001
Harrison, T. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-46687-9_12
(2018) · Elsevier eBooks · doi:10.1016/b978-0-08-102474-4.00023-6
Maindonald, J. H. (2019) · Australian & New Zealand Journal of Statistics · doi:10.1111/anzs.12281
Rittman, M. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-315-6
Xu, X., & Hu, S. (2019) · Springer eBooks · doi:10.1007/978-981-10-4857-9_1-1 · Cited by 1
Improving quality of preclinical academic research through auditing:Preprint
Kurreck, C., Castaños‐Vélez, E., Freyer, D., Blumenau, S., Przesdzing, I., Bernard, R., & Dirnagl, U. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/y8tpd
Kammerer, J. J. (2016) · Sage eBooks · doi:10.4135/9781483349985.n407
Metadata
- Authors
- Begley, C. G., & Ellis, L. M.
- Affiliations
- Amgen (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Ellis, Lee M.
- Venue
- Nature
- Published
- 2012-03-28
- Volume
- 483
- Issue
- 7391
- Pages
- 531-533
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1987777080
- Semantic Scholar
- 1a81d3d1e8a983e0551edf485f4ac1a8cdd7fea4
- Cited by
- 2,979
- References
- 5
- Citations by year
- 2026: 106 · 2025: 116 · 2024: 127 · 2023: 169 · 2022: 179 · 2021: 206 · 2020: 236 · 2019: 255 · 2018: 262 · 2017: 271 · 2016: 283 · 2015: 262 · 2014: 226 · 2013: 133 · 2012: 62
- FWCI
- 210.63
- Type
- journal article
- Language
- en
- Update notices
- correction (2012-05-02)
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- preclinical cancer research, research standards, publication practices, research incentives, translational research, clinical trials
- MeSH terms
- Animals, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Research Design, Reproducibility of Results, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.